Anti-Müllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age

Laven, Joop S.E.; Mulders, A.; Visser, Jenny A.; Themmen, Axel P. N.; Jong, Frank H. de; Fauser, Bart C.J.M.

doi:10.1210/jc.2003-030932

Cited by 474 publications

(388 citation statements)

References 39 publications

(42 reference statements)

Supporting

Mentioning

306

Contrasting

Unclassified

Order By: Relevance

“…AMH concentrations are strongly associated with the main phenotypic features of PCOS, including ovulatory dysfunction and HA. Amenorrheic women with PCOS display higher serum AMH levels than do oligomenorrheic women with PCOS [40].…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose We assessed the utility of using anti-Müllerian hormone (AMH) and clinical features of polycystic ovary syndrome (PCOS), polycystic ovarian morphology (PCOM), oligo/amenorrhea (OA), and hyperandrogenism (HA) for diagnosing PCOS, and compared their diagnostic accuracy with those of classical diagnostic systems. Methods A total of 606 females were admitted to a university hospital with menstrual irregularities or symptoms of hyperandrogenism were enrolled in this cross-sectional study. Fasting blood samples were collected. Pelvic and/or abdominal ultrasonography and clinical examination were performed. Patients were evaluated for the presence of PCOS according to conventional diagnostic criteria. The diagnostic performance of using serum AMH levels alone and in various combinations with the clinical features of PCOM, OA, and HA were investigated. Results For the diagnosis of PCOS, the combination of OA and/or HA with AMH showed 83 % sensitivity and 100 % specificity according to the Rotterdam criteria; 83 % sensitivity and 89 % specificity according to the National Institutes of Health (NIH) criteria; and 82 % sensitivity and 93.5 % specificity according to the Androgen Excess Society (AES) criteria. Conclusions The serum AMH level is a useful diagnostic marker for PCOS and is correlated with conventional diagnostic criteria. The combination of AMH level with OA and/ or HA markedly increased the clinical scope for PCOS diagnosis and can be introduced as a possible objective criterion for the diagnosis of this disease.

show abstract

Section: Discussionmentioning

confidence: 85%

“…Whether there is an association between serum AMH levels and different anthropometric, metabolic, and endocrine parameters in patients with PCOS is controversial; age has been reported to be both negatively related [38,40] and not correlated [41] with AMH. We found a negative correlation between age and AMH.…”

Section: Discussionmentioning

confidence: 99%

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Şahmay

Aydın

Öncül

et al. 2013

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that increased levels of anti-Müllerian hormone (AMH) are associated with follicular excess from polycystic ovarian morphology (PCOM) in women with PCOS [Chen et al 2008;Laven et al 2004;Pigny et al 2006;Pigny et al 2003]. AMH, also known as Müllerian inhibitory substance (MIS), is primarily produced by granulosa cells of secondary, preantral, and small antral follicles [Baarends et al 1995;Weenen et al 2004].…”

Section: Introductionmentioning

confidence: 99%

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Hua

et al. 2014

Systems Biology in Reproductive Medicine

View full text Add to dashboard Cite

(2015) The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome, Systems Biology in Reproductive Medicine, 61:2, 103-109, DOI: 10.3109/19396368.2014.973123 To link to this article: https://doi.org/10. 3109/19396368.2014 AbstractThe aim of this study was to ascertain whether higher levels of serum anti-Mü llerian hormone (AMH) are associated with the ovarian follicular arrest in women with polycystic ovary syndrome (PCOS). This prospective study compared AMH levels between serum and dominant follicular fluid (FF) in ovulatory polycystic ovary (PCO) women and anovulatory (menstrual cycle !60 days.) PCOS women. All 102 women provided a baseline hormone profile and underwent controlled ovarian hyperstimulation (COH). The anovulatory PCO women had a similar body mass index (BMI), antral follicle count (AFC), and baseline serum AMH levels as the ovulatory PCO women except that their median luteinizing hormone (LH; 10.0 mIU/ml), testosterone (T) (0.61 ng/l), and androstenedione (A) (3.47 ng/l) levels were significantly higher than ovulatory PCO women (4.9 mIU/m; 0.43 ng/l and 2.09 ng/l, respectively). The ovarian response to gonadotropin stimulation during COH including serum AMH on the day of HCG administration and dominant FF AMH at 36 hours after HCG administration, total follicle stimulating hormone (FSH) dose administrated, peak E 2 , (estrogen) levels and number of occytes retrieved were all similar between women with anovulatory and ovulatory PCO. Using multiple regression analysis it was found that an important independent determinant affecting AMH was AFC, as opposed to LH and T. Logistic regression analysis showed that the two most important factors affecting ovulation were serum LH and T, whereas serum AMH and AFC were not selected for inclusion in the model. The reduction in AMH during COH occurs as a consequence of dominant follicles with a corresponding reduction in small antral follicle number. Elevated serum AMH levels in PCO women seem to be related only to follicular excess and not follicular arrest.

show abstract

Section: Introductionmentioning

confidence: 99%

“…AMH has therefore been proposed as a novel clinical marker of ovarian reserve [1]. Another major reason for the interest in AMH is the fact that serum AMH levels are increased significantly in women with polycystic ovary syndrome (PCOS) when compared with normoovulatory women [2,3].PCOS is the most frequent cause of anovulatory infertility and hyperandrogenism in young women [4]. Women with this syndrome are characterized by an excessive number of small antral follicles (2-3 fold that of normal ovaries) [5].…”

mentioning

confidence: 99%

Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients

Wei

Gong

2012

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To investigate whether serum Anti-Müllerian hormone (AMH) on day 3 could predict controlled ovarian stimulation and reproductive outcomes in women with polycystic ovary syndrome. Methods A total of 164 PCOS patients undergoing their first IVF treatment cycle were prospectively included. Serum AMH levels on cycle day 3 was measured. The controlled ovarian stimulation and clinical outcomes for the study population were divided according to the <25th, 25 to 75th, or >75th percentile of serum day-3 AMH. Results Estradiol levels on hCG day and the number of retrieved oocytes significantly increased with increasing serum AMH levels, while total consumption of gonadotropin dose showed a significant decrease (P<0.05). Fertilization rate and the number of good quality embryos were comparable among the low, average and high groups (P>0.05). Embryo implantation rates in the high AMH group was significantly inferior to those with low and average AMH concentration (27 versus 48.8 and 50%, P<0.01). Clinical pregnancy rates was lower in the high AMH group than that of the low and average group (45.9 versus 65 and 66.7%, P00.09), but this difference was only close to statistical significance. In addition, ordinal regression analysis indicated that LH level was the only independent predictor of embryo implantation rates (P00.017). Conclusions In PCOS women, AMH levels on day 3 of the IVF stimulation cycle positively predict ovarian response to gonadotrophins. However, the women with high AMH levels had a significantly decreased IR, which may be due to remarkably increased LH concentrations.Keywords Anti-Müllerian hormone . Assisted reproduction . Polycystic ovary syndrome . Serum AMH Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance (MIS), is producted specifically by granulose cells of early developing pre-antral and small antral follicles in the ovary, and declines with advancing age. AMH has therefore been proposed as a novel clinical marker of ovarian reserve [1]. Another major reason for the interest in AMH is the fact that serum AMH levels are increased significantly in women with polycystic ovary syndrome (PCOS) when compared with normoovulatory women [2,3].PCOS is the most frequent cause of anovulatory infertility and hyperandrogenism in young women [4]. Women with this syndrome are characterized by an excessive number of small antral follicles (2-3 fold that of normal ovaries) [5]. As an exclusively granulosa cell product, it was initially proposed that the rise in serum AMH in PCOS was a consequence of the increased small antral follicle number in these ovaries [6]. The Capsule In PCOS women, high AMH levels on day 3 of the IVF stimulation cycle predict high ovarian response to gonadotrophins, but low embryo implantation rates.

show abstract

Anti-Müllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age

Cited by 474 publications

References 39 publications

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms

The relationship between serum anti-Müllerian hormone levels and the follicular arrest for women with polycystic ovary syndrome

Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients

Contact Info

Product

Resources

About